The global hyperlipidemia drug market is anticipated to grow at a significant CAGR during the forecast period. The major factor for the growth of the global hyperlipidemia market during the forecast period is the rapidly growing consumption of dairy products along with the sedentary lifestyle is fueling the market. Statins are the first line of treatment for hyperlipidemia. The expiration of patents of branded drugs will lead to the genericization of these drugs, hence bringing down the cost of treatment effectively and in turn boosting the growth of the market.
A full report of Hyperlipidemia Drug Market is available at: https://www.omrglobal.com/industry-reports/hyperlipidemia-drug-market-share
The new launches of drugs having different mechanisms such as ACL inhibition, DGAT2 inhibition, and anti-ANGTPL-3 are proving to be more effective while they reduce the effect of CVD. Some of the key global market players include Amgen Inc., Bristol-Myers Squibb Co., Daiichi Sankyo Co., Ltd., Ionis Pharmaceuticals, Inc., Mylan N.V, GlaxoSmithKline PLC Pfizer, Inc., Sanofi-Aventis S.A., Merck & Co., Inc., Dr Reddy’s Laboratories, Ltd. and others. For instance, in February 2020, the US FDA approved the first non-statin drug for the lowering of cholesterol levels called NEXLIZET developed by Esperion’s.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/hyperlipidemia-drug-market-share
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Drug Class
- Competitive Landscape – Amgen Inc., Bristol-Myers Squibb Co., Daiichi Sankyo Co., Ltd., Ionis Pharmaceuticals, Inc. and others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Hyperlipidemia Drug Market by Segment
By Drug Class
- Statins
- PCSK9 Inhibitors
- Nicotinic Acid
- Combination Therapy
- Fibrates
This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.
